Melanoma patients with heterozygous HLA-C group expression (11/32, 34%) can not achieve KIR-ligand incompatibility with any healthy donor, and were therefore excluded (Figure 1A “C1&C2”). This evidence concerns the gene HLA-C and melanoma.